Jubilant Life shares fall on US FDA warning letter
REUTERS - Shares in Jubilant Life Sciences Ltd (JULS.NS) fell as much as 6.9 percent on Wednesday after U.S. health regulators issued a warning letter to the company, citing "significant violations" of manufacturing standards at its facility in Canada.
The U.S. Food and Drug Administration may hold drug approvals until Jubilant HollisterStier General Partnership takes necessary corrective steps, Jubilant said in a statement.
Other bigger Indian companies such as Dr. Reddy's Laboratories Ltd (REDY.NS), Ranbaxy Laboratories Ltd (RANB.NS), Sun Pharmaceutical Industries Ltd (SUN.NS) and Aurobindo Pharma (ARBN.NS) have all received regulatory warning letters on compliance over the last four years.
The company said its on-going manufacturing, distribution and sale of products would not be affected by the warning letter, and it plans to respond to the drug regulator on or before March 15.
Shares in Jubilant Life Sciences, which has a market value of about $548.5 million, fell 4.25 percent to 178 rupees. They earlier touched a low of 173 rupees. The Sensex was up 0.67 percent.
(Reporting by Kaustubh Kulkarni in Mumbai; Editing by Anand Basu)
- Tweet this
- Share this
- Digg this
- Islamic State fighters kill 220 Iraqis from tribe that opposed them
- UPDATE 7-Apple's Cook: "I'm proud to be gay"
- UPDATE 1-Islamic State fighters kill 220 Iraqis from tribe that opposed them
- Bike-riding US nurse defies Ebola quarantine, on collision course with governor
- Apple's Cook: "I'm proud to be gay"
India's universal health plan that aims to offer guaranteed benefits to a sixth of the world's population will cost an estimated 1.6 trillion rupees ($26 billion) over the next four years, a senior health ministry official said. Full Article